Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer

被引:18
|
作者
Chang, Myung Hee [1 ,5 ]
Lee, Kyungji [2 ]
Lee, Kyo-Young [2 ]
Kim, Yeon Sil [3 ]
Kim, Young Kyoon [4 ]
Kang, Jin-Hyoung [1 ]
机构
[1] Catholic Univ, Div Oncol, Dept Med, Seoul St Marys Hosp,Sch Med, Seoul 137701, South Korea
[2] Catholic Univ, Dept Hosp Pathol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[3] Catholic Univ, Dept Radiat Oncol, Sch Med, Seoul St Marys Hosp, Seoul 137701, South Korea
[4] Catholic Univ, Div Pulmonol, Sch Med, Seoul St Marys Hosp,Dept Med, Seoul 137701, South Korea
[5] Ilsan Hosp, Div Hematooncol, Dept Med, Natl Hlth Insurance Corp, Koyang, South Korea
关键词
Small cell lung cancer; integrin ss 1; E-cadherin; rac1; RHO-GTPASES; PANCREATIC-CARCINOMA; CATENIN EXPRESSION; MEDIATED ADHESION; SURVIVAL; HYPERMETHYLATION; ACTIVATION; RECEPTORS; BINDING; IQGAP1;
D O I
10.1111/j.1600-0463.2011.02788.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Integrin beta(1) mediates cellular adhesion to the extracellular matrix (ECM) and is correlated with highly invasive and metastatic behavior in small cell lung cancer (SCLC). E-cadherin (ECAD) is a calcium-dependent cell-cell adhesion receptor that restricts invasion of cells and reduces metastasis. Rac1 is involved in the regulation of the actin cytoskeleton, adhesion, migration, invasion, and tumor metastasis. The aim of this study was to examine integrin beta(1), ECAD and rac1 expression in SCLC and to analyze the prognostic value of these markers in patients with SCLC. We analyzed integrin beta(1), ECAD, and rac1 expression in 112 SCLC tissues by immunohistochemical staining. Correlative analyses between integrin beta(1), ECAD, and rac1 expression and cliniopathological factors were performed. A total of 65 patients had extensive disease (ED) (58%), and 47 had limited disease (LD) (42%). The median follow-up duration was 61 months (range: 14-117 months), and the median progression free survival (PFS) and overall survival (OS) were 6.1 months (range: 4.8-7.4 months) and 9.7 months (range: 8.1-11.3 months), respectively. The expression of integrin beta(1), ECAD, and rac1 protein was observed in 64, 73, and 99 of SCLC tissues, respectively. The correlative analyses between integrin beta(1), ECAD, or rac1 expression and various clinical parameters did not show any statistical significance. However, the ECAD expression was associated with OS in the entire cohort. In contrast, the expression of integrin beta(1) and rac1 was not associated with PFS or OS. In a subgroup analysis, patients with less than two metastasis had significantly longer OS (p = 0.047) if their tumors expressed integrin beta(1) compared to those without integrin beta(1) expression. In addition, OS was longer for patients with ECAD positive tumors compared to those whose tumors did not express ECAD in males (p = 0.032) and patients who never smoked (p < 0.001). Multivariate analysis showed that LD (p = 0.004), overall response rate (p = 0.003), and expression of ECAD (p = 0.015) were the independent good prognostic factors for OS. LD (p = 0.024), overall response rate (p < 0.001), and less than two metastasis (p = 0.003) were prognostic factors for longer PFS. These results suggest that ECAD expression may be useful as a prognostic indicator in patients with SCLC.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 50 条
  • [21] The expression of E-cadherin as a prognostic factor in breast cancer
    Kawahara, F
    Noguchi, M
    Yagasaki, R
    Minami, M
    Earashi, M
    Kinoshita, K
    Ohta, N
    Taniya, T
    Miyazaki, I
    ONCOLOGY REPORTS, 1997, 4 (02) : 401 - 405
  • [22] Expression and Clinical Significance of CD82/KAI1 and E-cadherin in Non-Small Cell Lung Cancer
    Wu Shiwu
    Yu Lan
    Song Wenqing
    Zhou Lei
    Tao Yisheng
    ARCHIVES OF IRANIAN MEDICINE, 2012, 15 (11) : 707 - 712
  • [23] Prognostic and clinicopathologic significance of AEG-1/MTDH and E-cadherin expression in human gallbladder carcinoma
    Xu, Song-Tao
    Ma, Yong-Chao
    Wang, Cai-Hong
    Xu, Yue
    Gu, Guo-Jian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (12): : 6025 - 6031
  • [24] Prognostic role of E-cadherin in patients with advanced serous ovarian cancer
    Bacic, Boris
    Haller, Herman
    Mrklic, Ivana
    Kosta, Vana
    Caric, Ana
    Tomic, Snjezana
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 287 (06) : 1219 - 1224
  • [25] Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer
    Wang, Guiying
    Hu, Xiaohua
    Lu, Chenqi
    Su, Chengchang
    Luo, Shijing
    Luo, Z. W.
    LUNG CANCER, 2008, 62 (02) : 162 - 172
  • [26] Aberrant Expression of E-cadherin in Lung Tissues of Patients with Probable Lung Cancer
    Yuan, Yu-Lin
    Wang, Yu-Ming
    Liu, Hua
    Qin, Gui-Fang
    Tang, Ai-Guo
    Duan, Yong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 5149 - 5153
  • [27] Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma
    Zou, Jian
    Yang, Hui
    Chen, Fei
    Zhao, Houyu
    Lin, Pin
    Zhang, Jie
    Ye, Huiping
    Wang, Lihong
    Liu, Shixi
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2010, 19 (01) : 11 - 17
  • [28] Clinicopathological significance and prognostic value of E-cadherin expression in non-small cell lung cancer A protocol for systematic review and meta-analysis
    Chao, Dong
    Hu, Gawei
    Li, Qingxin
    MEDICINE, 2021, 100 (07) : E24748
  • [29] Clinicopathological Significance of E-cadherin and PCNA Expression in Hunman Non-small Cell Lung Cancer
    Jianwei Ma1 Kai Fan2 Yanli Zhang2 Dawei Song2 Jianmei Ma2 1 Department of thoracic surgery
    Chinese Journal of Clinical Oncology, 2008, (02) : 87 - 92
  • [30] Clinical Outcomes of Downregulation of E-cadherin Gene Expression in Non-small Cell Lung Cancer
    Zheng, Shi-Ying
    Hou, Jing-Yu
    Zhao, Jun
    Jiang, Dong
    Ge, Jin-Feng
    Chen, Sheng
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (04) : 1557 - 1561